AU2016308080A1 - Honokiol and magnolol formulations with increased stability and improved uptake, and methods of use thereof - Google Patents

Honokiol and magnolol formulations with increased stability and improved uptake, and methods of use thereof Download PDF

Info

Publication number
AU2016308080A1
AU2016308080A1 AU2016308080A AU2016308080A AU2016308080A1 AU 2016308080 A1 AU2016308080 A1 AU 2016308080A1 AU 2016308080 A AU2016308080 A AU 2016308080A AU 2016308080 A AU2016308080 A AU 2016308080A AU 2016308080 A1 AU2016308080 A1 AU 2016308080A1
Authority
AU
Australia
Prior art keywords
formulation
honokiol
magnolol
less
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016308080A
Other languages
English (en)
Inventor
Bomi P. Framroze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST IP Holding AG
Original Assignee
ST IP Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST IP Holding AG filed Critical ST IP Holding AG
Publication of AU2016308080A1 publication Critical patent/AU2016308080A1/en
Priority to AU2022201271A priority Critical patent/AU2022201271A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/57—Magnoliaceae (Magnolia family)
    • A61K36/575—Magnolia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Anesthesiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016308080A 2015-08-17 2016-01-18 Honokiol and magnolol formulations with increased stability and improved uptake, and methods of use thereof Abandoned AU2016308080A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022201271A AU2022201271A1 (en) 2015-08-17 2022-02-24 Honokiol and Magnolol Formulations with Increased Stability and Improved Uptake, and Methods of Use Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2534DE2015 2015-08-17
IN2534/DEL/2015 2015-08-17
PCT/IN2016/050021 WO2017029683A1 (en) 2015-08-17 2016-01-18 Honokiol and magnolol formulations with increased stability and improved uptake, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022201271A Division AU2022201271A1 (en) 2015-08-17 2022-02-24 Honokiol and Magnolol Formulations with Increased Stability and Improved Uptake, and Methods of Use Thereof

Publications (1)

Publication Number Publication Date
AU2016308080A1 true AU2016308080A1 (en) 2018-03-22

Family

ID=58051448

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016308080A Abandoned AU2016308080A1 (en) 2015-08-17 2016-01-18 Honokiol and magnolol formulations with increased stability and improved uptake, and methods of use thereof
AU2022201271A Abandoned AU2022201271A1 (en) 2015-08-17 2022-02-24 Honokiol and Magnolol Formulations with Increased Stability and Improved Uptake, and Methods of Use Thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022201271A Abandoned AU2022201271A1 (en) 2015-08-17 2022-02-24 Honokiol and Magnolol Formulations with Increased Stability and Improved Uptake, and Methods of Use Thereof

Country Status (12)

Country Link
US (1) US10328090B2 (enExample)
EP (1) EP3337487B1 (enExample)
JP (1) JP6663993B2 (enExample)
KR (1) KR20180050331A (enExample)
AU (2) AU2016308080A1 (enExample)
CA (1) CA2995834A1 (enExample)
DK (1) DK3337487T3 (enExample)
ES (1) ES2873601T3 (enExample)
HU (1) HUE054161T2 (enExample)
PL (1) PL3337487T3 (enExample)
PT (1) PT3337487T (enExample)
WO (1) WO2017029683A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3769174B1 (en) 2018-03-21 2022-07-06 Realtime Robotics, Inc. Motion planning of a robot for various environments and tasks and improved operation of same
KR20200083304A (ko) * 2018-12-28 2020-07-08 충북대학교 산학협력단 일본 목련 추출물을 유효성분으로 함유하는 불안장애의 예방 또는 치료용 약학적 조성물
US20220015406A1 (en) * 2019-01-25 2022-01-20 Flaask, Llc Compositions and Methods for Improving Quality of Life in Patients with Autism Spectrum Disorder
CN110585140A (zh) * 2019-07-08 2019-12-20 苏州海特比奥生物技术有限公司 一种和厚朴酚纳米聚合物胶束冻干制剂及其制备方法
US12213505B2 (en) * 2021-07-05 2025-02-04 Healthy Ingredient Solutions, LLC Composition for promoting restful sleep and methods of making and using the same
WO2025136962A1 (en) * 2023-12-19 2025-06-26 Rebalance Health, Inc. Compositions for reducing hot flashes and symptoms associated with anxiety and formulations thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582735B2 (en) 2000-12-15 2003-06-24 Npi, Llc. Compositions and methods of use for extracts of magnoliaceae plants
CN1723011A (zh) 2002-06-25 2006-01-18 Wm·雷格利Jr·公司 含有厚朴提取物的口气清新和口腔清洁产品
US7632525B2 (en) 2002-06-25 2009-12-15 Wm. Wrigley Jr. Company Breath freshening and oral cleansing product with magnolia bark extract in combination with surface active agents
RU2396941C2 (ru) 2005-12-02 2010-08-20 Джи Ай Си ИННОВАТИОНЗ КОМПАНИ Наполнители с экстрактом коры магнолии для ухода за полостью рта
US7544377B2 (en) 2005-12-02 2009-06-09 Gic Innovations Company Chewable compositions with fast release magnolia bark extract
WO2007064505A1 (en) 2005-12-02 2007-06-07 Gic Innovations Company Confectionary compositions with magnolia bark extract
KR101527829B1 (ko) 2007-04-19 2015-06-12 마리 케이 인코포레이티드 마그놀리아 추출물 함유 조성물
WO2011115476A1 (en) 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
DE102010015791A1 (de) * 2010-04-20 2011-10-20 Beiersdorf Ag Wirkstoffkombinationen aus Magnolienrindenextrakt und polyethoxylierten Verbindungen
DE102010015792A1 (de) * 2010-04-20 2011-10-20 Beiersdorf Ag Wirkstoffkombinationen aus Magnolienrindenextrakt und oberflächenaktiven Agentien
RU2606841C2 (ru) * 2010-09-03 2017-01-10 Н.В. Нютрисиа Способ и препарат для лечения или профилактики тревожности или нейрогенеза
FR2970294B1 (fr) * 2011-01-11 2012-12-28 Peugeot Citroen Automobiles Sa Ligne d'echappement pour un moteur a combustion interne
IE20110008A1 (en) 2011-01-12 2012-08-01 Patrick Thomas Prendergast Compositions for alleviating:- stress, anxiety, depression and aiding with weight loss
WO2013043151A1 (en) * 2011-09-19 2013-03-28 Framroze Bomi P Edible oil with a high concentration of poly-unsaturated fatty acids
EP2759065B8 (en) * 2011-09-20 2023-05-03 VivaQuant, Inc. Physiological signal denoising

Also Published As

Publication number Publication date
PL3337487T3 (pl) 2021-12-06
JP2018528266A (ja) 2018-09-27
JP6663993B2 (ja) 2020-03-13
ES2873601T3 (es) 2021-11-03
KR20180050331A (ko) 2018-05-14
AU2022201271A1 (en) 2022-03-17
HUE054161T2 (hu) 2021-08-30
EP3337487A4 (en) 2019-04-03
CA2995834A1 (en) 2017-02-23
US20180147220A1 (en) 2018-05-31
EP3337487A1 (en) 2018-06-27
EP3337487B1 (en) 2021-02-24
PT3337487T (pt) 2021-05-27
DK3337487T3 (da) 2021-05-25
US10328090B2 (en) 2019-06-25
WO2017029683A1 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
AU2022201271A1 (en) Honokiol and Magnolol Formulations with Increased Stability and Improved Uptake, and Methods of Use Thereof
KR20190084036A (ko) 식물 공급원으로부터 칸나비노이드의 선택적 추출 방법
JPH1036276A (ja) 抗アレルギー剤及びこれを含有する抗アレルギー性化粧料並びに食品
CA2696207A1 (en) Fraction of melissa leaf extract having angiogenesis and mmp inhibitory activities, and composition comprising the same
JP5467795B2 (ja) β−セクレターゼ阻害剤
Mangrulkar et al. A comprehensive review on pleiotropic effects and therapeutic potential of soy lecithin
KR102598042B1 (ko) 중대가리풀 추출물을 포함하는 항염 및 자가면역 질환 예방 및 치료용 조성물 및 이의 제조 방법
JP6043923B2 (ja) 食事摂取に伴う血中中性脂肪上昇抑制剤
JP7655920B2 (ja) 認知障害の治療に使用する組成物
JP2011510016A (ja) アクチニディアおよびステロイドによって構成されている組合せ療法、ならびにこれらの使用
JP2013194031A (ja) 骨形成促進剤
CN107106621A (zh) 包含大花马齿苋提取物或其馏分作为活性成分用于预防或治疗神经炎症或者神经退行性疾病的药物组合物
JP5013659B2 (ja) アセチルコリンエステラーゼ阻害剤
JP7770644B2 (ja) 神経細胞変性抑用組成物
JP2004067526A (ja) アトピー性疾患の症状の予防・緩和に有効な組成物
US20240207348A1 (en) Herbal composition for cancer
JP2001163772A (ja) 抗白内障剤
JP2010235524A (ja) 花粉荷を含有する抗ヒスタミン剤
US20110038943A1 (en) Milkweed seed oil administered to animals
JP6072201B1 (ja) アセチルコリンエステラーゼ阻害剤及びその用途
JP6805514B2 (ja) 脱脂米ぬか抽出物を含有する組成物
RU2571503C1 (ru) Фармацевтическая композиция, обладающая свойствами активировать витамин д рецепторы
CN119969583A (zh) 一种缓解抑郁的组合物及其制备方法和应用
JP2018024654A (ja) プロポリスのミセル化抽出物を有効成分とする認知機能改善剤

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted